Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jordan Chervin"'
Autor:
Eytan Stein, Sheng F Cai, Ying Huang, Andrew Dunbar, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Michael M. Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail B. Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Molly Martycz, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine
Publikováno v:
Blood. 140:2016-2019
Autor:
Joseph GW. McCarter, David Nemirovsky, Christopher A. Famulare, Noushin Farnoud, Abhinita S. Mohanty, Zoe S. Stone-Molloy, Jordan Chervin, Brian J. Ball, Zachary D. Epstein-Peterson, Maria E. Arcila, Aaron J. Stonestrom, Andrew Dunbar, Sheng F. Cai, Jacob L. Glass, Mark B. Geyer, Raajit K. Rampal, Ellin Berman, Omar I. Abdel-Wahab, Eytan M. Stein, Martin S. Tallman, Ross L. Levine, Aaron D. Goldberg, Elli Papaemmanuil, Yanming Zhang, Mikhail Roshal, Andriy Derkach, Wenbin Xiao
Accurate classification and risk stratification is critical for clinical decision making in AML patients. In the newly proposed World Health Organization (WHO) and International Consensus classifications (ICC) of hematolymphoid neoplasms, the presenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6261f60ffb5931493bccbaa0395aca48
https://doi.org/10.1101/2022.12.26.22283876
https://doi.org/10.1101/2022.12.26.22283876
Autor:
Jordan Chervin, Ross L. Levine, Tara L. Lin, Ying Huang, William Blum, Sonja Marcus, Tibor Kovacsovics, Ashley O. Yocum, Franchesca Druggan, Gary J. Schiller, Brian J. Druker, Mona Stefanos, Uma Borate, Matthew C. Foster, Mark R. Litzow, John C. Byrd, Nyla A. Heerema, Robert H. Collins, Abigail B. Shoben, Wendy Stock, Leonard Rosenberg, Amy Burd, Michael Boyiadzis, James M. Foran, Rebecca L. Olin, Jo-Anne Vergilio, Prapti A. Patel, Maria R. Baer, Timothy L. Chen, Eytan M. Stein, Alice S. Mims
Publikováno v:
Blood. 136:27-30
Background: ENA is an oral, selective inhibitor of IDH2 approved for the treatment (Tx) of patients (pts) with relapsed/refractory IDH2 mutated (IDH2m) AML. Here we report the results of a Phase 2 expansion and Phase 1b of the Beat AML Master Trial P
Autor:
Kathryn E Kozak, Linda Ouyang, Susan J. McCall, Michael J. Mauro, Andriy Derkach, Alexandra Sherman, Raajit K. Rampal, Jordan Chervin, Ryan J. Daley, Christopher Famulare, Sejal Morjaria
Publikováno v:
Leukemia
Autor:
Jordan Chervin, John C. Byrd, Leonard Rosenberg, William Blum, Amy Burd, Sonja Marcus, Mona Stefanos, Jo-Anne Vergilio, Wendy Stock, Uma Borate, Brian J. Druker, Eytan M. Stein, Nyla A. Heerema, Maria R. Baer, Tibor Kovacsovics, Abigail B. Shoben, Ross L. Levine, Alice S. Mims, Prapti A. Patel
Publikováno v:
Blood. 132:287-287
The majority of patients with acute myeloid leukemia (AML), including nearly all patients older than age 60, present with multiple, sequentially acquired, somatic mutations. The 5-year overall survival (OS) for AML patients ≥ 60 with the current st